

Express Mail No.: EV 335 857 401 US**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Application of: *Bee et al.*

Confirmation No. 4949

Application No.: 09/880,732

Group Art Unit: 1634

Filed: June 12, 2001

Examiner: JOHANNSEN, DIANA B

For: Assay For Genetic Polymorphisms
Using Scattered Light Detectable LabelsAttorney Docket No.: 11032-017
(formerly 089498-0402)**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby directs the Examiner's attention to references AA-BK listed on the attached revised form PTO-1449 entitled "List of References Cited by Applicant." Legible copies of references AA-BK are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Consequently, Applicant respectfully declines to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicant submits herewith a "revised form PTO-1449" entitled "List of References Cited" instead of "List of Prior Art Cited."

NY2: 1433597.1

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, pursuant to 37 C.F.R. § 1.97(b), no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP deposit account no. 16-1150. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 28, 2003

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

By: T. Christopher Tsang 40,258
T. Christopher Tsang (Reg. No.)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

11032-017-999

APPLICATION NO

09/880,732

APPLICANT

Bee et al.

FILING DATE

June 12, 2001

GROUP

1634

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3,939,350	2/27/76	Kronick et al.	250	365	
	AB	4,313,734	2/2/82	Leuversing	23	230 B	
	AC	4,597,944	7/1/86	Cottingham	422	73	
	AD	4,647,544	3/3/87	Nicoli et al.	436	518	
	AE	4,979,821	12/25/90	Schutt	356	246	
	AF	5,017,009	5/21/91	Schutt et al.	358	338	
	AG	5,100,805	3/31/92	Ziege et al.	436	517	
	AH	5,350,697	9/27/94	Swope	436	527	
	AI	5,552,086	9/3/96	Siiman et al.	252	408.1	
	AJ	5,585,241	12/17/96	Lindmo	435	6	
	AK	5,589,401	12/31/96	Hansen et al.	436	525	
	AL	5,841,534	11/24/98	Lorenz	356	336	
	AM	5,843,651	12/1/98	Stimpson	435	6	
	AN	5,851,777	12/22/98	Hunter et al.	435	7.1	
	AO	5,981,180	11/9/99	Chandler et al.	435	6	
	AP	6,214,560	4/10/01	Yguerabide et al.	435	7.1	
	AQ	6,586,193	7/1/032	Yguerabide et al.	735	7.92	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AR	WO 91/10745	6/25/91	PCT				
	AS	WO 96/09532	3/28/96	PCT				
	AT	WO 99/20789	4/29/99	PCT				
	AU	EP 0 759 476	2/26/97	EPC				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AV	Bao et al. High-sensitivity detection of DNA hybridization on microarrays using resonance light scattering. Anal Chem. 2002 Apr 15;74(8):1792-7
----	---

O I P E AUG 28 2003 PATENT & TRADEMARK OFFICE	AW	Bertilsson et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther. 1992 Apr;51(4):388-97
	X	Cholerton et al. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci. 1992 Dec;13(12):434-9. Review
	AY	Daly et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 1996 Jun;6(3):193-201
	AZ	Elghanian et al. Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science. 1997 Aug 22;277(5329):1078-81
	BA	Hamelin et al. CYP2D6 mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy. 1999 Sep;19(9):1057-63
	BB	Jennes et al. Synthesis and use of colloidal gold-coupled receptor ligands. Methods Enzymol. 1986;124:36-47
	BC	Kimura et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989 Dec;45(6):889-904
	BC	Knodell et al. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology. 1991 Dec;101(6):1680-91
	BE	Labuda et al. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal Biochem. 1999 Nov 1;275(1):84-92
	BF	Phillips and Shephard. eds. <i>Cytochrome P450 Protocols</i> . Vol. 107, Humana Press, 1998
	BG	Relling et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991 Sep;50(3):308-13
	BH	Schultz et al. Single-target molecule detection with nonbleaching multicolor optical immunolabels. Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):996-1001
	BI	Steiner et al. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin. Pharmacol Ther. 1998, 44:431-5
	BJ	Stuven et al. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics. 1996 Oct;6(5):417-21
	BK	van der Weide et al. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem. 1999 Nov;36 (Pt 6):722-9.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.